Drug development based on an "innovation supply chain" could stifle innovation if drugmakers push small biotech partners to follow a set route, writes Katrine Bosley, former CEO of Avila Therapeutics. "The more innovative the science, the more likely it is that the real challenge is to cultivate a new vision," she writes. Two-way, iterative partnerships bring together big drugmakers' experience with small biotechs' innovation, Bosley writes.
Innovation supply chain model risks "teaching to the test"
SmartBrief Job Listings for Health Care
|Director, Product Policy||
America's Health Insurance Plans (AHIP)
|Chief Medical Officer||
New Century Health
University of Virginia
|Associate/Deputy General Counsel* for Agriculture & Environment||
|Washington, DC, DC|
|Counsel II - Intellectual Property - Patent Litigation||
Gilead Science Inc
|Foster City, CA|